RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Clinical trials for RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo aims to control Tough-to-Treat CLL
Disease control Recruiting nowThis study tests whether combining two or three targeted drugs can better control chronic lymphocytic leukemia (CLL) that has returned or not responded to prior treatment. About 168 adults with high-risk CLL or small lymphocytic lymphoma will receive acalabrutinib and venetoclax,…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 03:30 UTC
-
Engineered immune cells take on tough blood cancers in new trial
Disease control Recruiting nowThis early-stage trial tests a new type of cell therapy for people with certain blood cancers (like lymphoma and leukemia) that have returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recogni…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Sumithira Vasu • Aim: Disease control
Last updated May 26, 2026 03:24 UTC
-
New drug cocktail aims to wipe out Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a combination of two drugs, acalabrutinib and venetoclax, in people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has returned or stopped responding to treatment. The goal is to see if this drug pair can kill more cancer cells and a…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 03:04 UTC
-
New CAR T-Cell attack on tough blood cancers shows early promise
Disease control Recruiting nowThis early-phase study tests a new treatment called MC10029, which uses a patient's own immune cells (T cells) that are modified in a lab to recognize and attack cancer cells. The therapy targets a protein called BAFFR found on certain blood cancer cells. The study includes up to…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 02:48 UTC
-
New combo therapy aims to speed up treatment for blood cancer patients
Disease control Recruiting nowThis study tests a faster way to increase the dose of sonrotoclax, a drug that blocks a protein helping cancer cells survive. It is given after initial treatment with zanubrutinib or rituximab. The trial includes 30 adults with chronic lymphocytic leukemia, small lymphocytic lymp…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 02:48 UTC
-
New hope for Hard-to-Treat blood cancers: targeted drug trial opens
Disease control Recruiting nowThis study tests a drug called mirdametinib in 20 adults whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has returned or stopped responding to treatment. The drug blocks a protein that helps cancer cells grow. The goal is to see if it can shrink tumor…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
Triple-Target CAR t cells take on tough blood cancers
Disease control Recruiting nowThis early-stage trial tests a new type of immunotherapy called TriCAR19.20.22 T cells for people with certain blood cancers (non-Hodgkin lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia) that have returned or not responded to prior treatments. The therapy…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New drug Q702 aims to boost immune system against Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests a new drug, Q702, in about 46 adults with certain blood cancers or related diseases that have not responded to standard treatments. Q702 works by helping the immune system attack cancer cells and supporting normal blood cell production. The main goals…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 19, 2026 11:47 UTC